Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-08 DOI:10.1080/14737140.2023.2245144

Igor Duquesne, Mohamad Abou Chakra, Lory Hage, Ugo Pinar, Yohann Loriot

{"title":"Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?","authors":"Igor Duquesne, Mohamad Abou Chakra, Lory Hage, Ugo Pinar, Yohann Loriot","doi":"10.1080/14737140.2023.2245144","DOIUrl":null,"url":null,"abstract":"Introduction: Liquid biopsies are used for the detection of tumor-specific elements in body fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder cancer (MIBC/NMIBC) or upper tract urothelial cancer (UTUC) remains poorly known and rarely mentioned in clinical guidelines.Areas covered: Herein, we provide an overview of current data regarding the use of liquid biopsies in urothelial tumors.Expert opinion: Studies that were included analyzed liquid biopsies using the detection of circulating tumor cells (CTCs), deoxyribonucleic acid (DNA), ribonucleic acid (RNA), exosomes, or metabolomics. The sensitivity of blood CTC detection in patients with localized cancer was 35% and raised to 50% in patients with metastatic cancer. In NMIBC patients, blood CTC was associated with poor prognosis, whereas discrepancies were seen in MIBC patients. Circulating plasma DNA presented a superior sensitivity to urine and was a good indicator for diagnosis, follow-up, and oncological outcome. In urine, specific bladder cancer (BC) microRNA had an overall sensitivity of 85% and a specificity of 86% in the diagnosis of urothelial cancer. These results are in favor of the use of liquid biopsies as biomarkers for in urothelial cancer management.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"995-1007"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2245144","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Liquid biopsies are used for the detection of tumor-specific elements in body fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder cancer (MIBC/NMIBC) or upper tract urothelial cancer (UTUC) remains poorly known and rarely mentioned in clinical guidelines.

Areas covered: Herein, we provide an overview of current data regarding the use of liquid biopsies in urothelial tumors.

Expert opinion: Studies that were included analyzed liquid biopsies using the detection of circulating tumor cells (CTCs), deoxyribonucleic acid (DNA), ribonucleic acid (RNA), exosomes, or metabolomics. The sensitivity of blood CTC detection in patients with localized cancer was 35% and raised to 50% in patients with metastatic cancer. In NMIBC patients, blood CTC was associated with poor prognosis, whereas discrepancies were seen in MIBC patients. Circulating plasma DNA presented a superior sensitivity to urine and was a good indicator for diagnosis, follow-up, and oncological outcome. In urine, specific bladder cancer (BC) microRNA had an overall sensitivity of 85% and a specificity of 86% in the diagnosis of urothelial cancer. These results are in favor of the use of liquid biopsies as biomarkers for in urothelial cancer management.

查看原文本刊更多论文

癌症尿路上皮检测、监测和预后的液体活检：未来的标准？

简介：液体活检用于检测体液中的肿瘤特异性元素。它们在肌肉/非肌肉浸润性膀胱癌症（MIBC/NMBC）或上尿路上皮癌症（UTUC）的预后和诊断中的应用仍然鲜为人知，临床指南中很少提及。涵盖的领域：在此，我们提供了关于在尿路上皮肿瘤中使用液体活检的最新数据概述。专家意见：包括使用循环肿瘤细胞（CTC）、脱氧核糖核酸（DNA）、核糖核酸（RNA）、外泌体或代谢组学检测分析液体活检的研究。局部癌症患者的血液CTC检测灵敏度为35%，转移性癌症患者的检测灵敏度提高到50%。在NMIBC患者中，血液CTC与不良预后相关，而在MIBC患者中则存在差异。循环血浆DNA对尿液具有较高的敏感性，是诊断、随访和肿瘤学结果的良好指标。在尿液中，特异性癌症（BC）微小RNA在诊断尿路上皮癌症方面的总体敏感性为85%，特异性为86%。这些结果有利于使用液体活检作为癌症尿路上皮管理的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.